Accelrys: Significant Upside Remains

An LA presenter continues to recommend Accelrys (NASDAQ: ACCL, $8.70). The stock is up 20% since it was presented back in October, but the presenter emphasizes that the company is still early in its multi-year growth phase. ACCL finalized its merger with Symyx in July and is now in a good position to become one of the leaders in the scientific informatics software space. Management has raised its estimates for synergies from the deal to the top-end of the previously provided range. The presenter stresses a substantial cross-sell upside to result from product integration.